Citable filing context
A's research view summarizes recent SEC filing context, starting with management_change from Sep 8, 2026.
| Filed | Item | Context |
|---|---|---|
| Sep 8, 2026 | management_change | Board Chair Koh Boon Hwee retired, Dow R. Wilson became chair, and Glenn Boehnlein joined the board. |
| Aug 26, 2026 | earnings | Agilent reported Q3 fiscal 2026 revenue of $1.88 billion, up 8.1%, and raised its full-year guidance. |
| Jun 25, 2026 | debt_offering | Agilent Technologies sold $600 million of 4.900% Senior Notes due 2032 in a private placement. |
| Aug 26, 2026 | Guidance: core_revenue_growth | 5.20 to 6.20 |
| Aug 26, 2026 | Guidance: core_revenue_growth | 5.80 to 6.00 |
| Aug 26, 2026 | Guidance: non_gaap_eps | 6.18 to 6.21 |
| Sep 1, 2026 | mda_quarterly | Agilent Technologies reported net revenue of $1,878 million for the third quarter of fiscal 2026, an 8 percent increase year-over-year, driven by normalized customer capital budgets and growth across all segments. Net income rose to $362 million, with operating margins expanding 3 percentage points to 23.6 percent, aided by higher sales volumes and a 1 percentage point benefit from International Emergency Economic Powers Act tariff refunds. The Life Sciences and Diagnostics Markets segment led growth with an 11 percent revenue increase to $746 million, bolstered by liquid chromatography, mass spectrometry, and the $950 million acquisition of pathology provider Biocare. Agilent CrossLab revenue grew 6 percent to $786 million on strong consumables and repair services demand, while Applied Markets rose 7 percent to $346 million, led by spectroscopy and vacuum products. To fund expansion, including the Frederick, Colorado advanced therapeutics facility, Agilent issued $600 million in 4.90 percent senior notes due 2032. Geopolitical risks from the Middle East conflict and dynamic tariff environments are being managed through supply chain optimization. Additionally, Agilent implemented restructuring plans expected to yield up to $130 million in combined annual cost savings. |
| Jun 1, 2026 | mda_quarterly | Agilent Technologies reported net revenue of $3.633 billion for the six months ended April 30, 2026, an 8% increase year-over-year, with net income rising to $644 million. Growth was broad across segments, led by Applied Markets (up 10%) and Life Sciences and Diagnostics Markets (up 8%). Key drivers included liquid chromatography, spectroscopy, and the Agilent Advanced Therapeutics CDMO business, with particular strength in pharmaceutical, chemical, and advanced materials markets, offsetting declines in academia and government spending. The company is expanding its Life Sciences and Diagnostics portfolio through the pending $950 million cash acquisition of Biocare. To enhance operating margins, Agilent is executing a restructuring plan targeting $90 million to $95 million in annual cost reductions. Financial risks include inflationary pressures from Middle East geopolitical tensions and evolving trade dynamics, though the company is seeking refunds for IEEPA tariffs following a Supreme Court invalidation. Capital expenditures are projected at $450 million for the year, primarily to expand advanced therapeutics manufacturing capacity in Frederick, Colorado. Shareholder returns remain a priority, evidenced by a $2 billion share repurchase program and consistent quarterly dividends. |
Source: SEC EDGAR filing text and events; period Sep 8, 2026; filed Sep 8, 2026.
A company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.